logo

For the Inventor, By the Inventor

Marseille, France

Innate Pharma

Calculating rank
USPTO Granted Patents = 68

% Expired Patents = 13.2



Trademarks = 1

Forward Citations = 240

Loading Chart...
Loading Chart...

68 inventors (with patents filed for the assignee):

goldMedal Laurent Gauthier (37 out of 42 patents)

silverMedal Carine Paturel (24 out of 25 patents)

bronzeMedal Benjamin Rossi (20 out of 20 patents)

4.  Mathieu Blery (12 out of 14 patents)

5.  Nadia Anceriz (10 out of 10 patents)

6.  Pascale Andre (10 out of 18 patents)

7.  Nicolai Wagtmann (9 out of 13 patents)

8.  Hélène Sicard (9 out of 9 patents)

9.  Ivan Perrot (8 out of 9 patents)

10.  Delphine Bregeon (8 out of 8 patents)

11.  Ariane Morel (7 out of 7 patents)

12.  Patrick Dennler (7 out of 7 patents)

13.  Eliane Fischer (7 out of 7 patents)

14.  Roger Schibli (6 out of 24 patents)

15.  Christian Belmant (6 out of 14 patents)


Core Competencies:
NK Cell Engagers
CD73 Blocking Antibodies
T Cell Lymphoma
Siglec Neutralizing Antibodies
KIR3DL2 Binding Agents
NKG2A Antibodies
Humanized Antibodies
Enzymatic Conjugation
Multispecific Proteins
TLR3 Binding Agents
Combination Therapy
Cancer Treatment

68 patents:

1. 12594343 - TREATMENT OF CANCER (2026-04-07),
2. 12528876 - CD73 BLOCKING ANTIBODIES (2026-01-20),
3. 12448442 - Treatment of T cell lymphoma (2025-10-21),
4. 12365731 - NKp46 binding agents (2025-07-22),
5. 12252543 - Multispecific NK engager protein (2025-03-18),
6. 12227569 - Humanized antibodies with increased stability (2025-02-18),
7. 12209126 - Treatment of cancer (2025-01-28),
8. 12202907 - Nucleic acids encoding and methods of producing proteins comprising antibody chains (2025-01-21),
9. 12084498 - Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma (2024-09-10),
10. 12037392 - Treatment regimens using anti-NKG2A antibodies (2024-07-16),
11. 11999784 - Treatment of peripheral T cell lymphoma (2024-06-04),
12. 11970535 - Treatment with anti-KIR3DL2 agents (2024-04-30),
13. 11958907 - CD73 blockade (2024-04-16),
14. 11891444 - Variable regions for NKp46 binding proteins (2024-02-06),
15. 11858990 - KIR3DL2 binding agents (2024-01-02),
Company Overview
Innate Pharma, based in Marseille, France, is a biotechnology company focused on developing innovative cancer immunotherapies. The company specializes in harnessing the power of the immune system to combat cancer, with a strong emphasis on technologies such as NK cell engagers and CD73 blocking antibodies. Their research extends to T cell lymphoma and includes the development of Siglec neutralizing antibodies, KIR3DL2 binding agents, and NKG2A antibodies, alongside humanized antibodies and enzymatic conjugation techniques.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Innate Pharma USPTO Patent Assignee Logo
68 Patents

#1 in Marseille

#384 in France

#10,894 in the World

Marseille, FR
Marseille, France

Innate Pharma

Forward Citations = 240

68 inventors:

goldMedal Laurent Gauthier (37 out of 42 patents)

silverMedal Carine Paturel (24 out of 25 patents)

bronzeMedal Benjamin Rossi (20 out of 20 patents)

4.  Mathieu Blery (12 out of 14 patents)

5.  Nadia Anceriz (10 out of 10 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Innate Pharma. Retrieved from https://idiyas.com/company/innate-pharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…